Abstract
The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.
Keywords: B cells, CLL, lymphoma, nanoparticles, chlorambucil, hydroxychloroquine, rituximab.
Current Clinical Pharmacology
Title:Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma
Volume: 5 Issue: 4
Author(s): Gustavo H. Marin, Eduardo Mansilla, Nelly Mezzaroba, Sonia Zorzet, Luis Nunez, Gustavo Larsen, Jose M. Tau, Alberto Maceira, Ruben Spretz, Carol Mertz, Sabrina Ingrao, Claudio Tripodo, Francesco Tedesco and Paolo Macor
Affiliation:
Keywords: B cells, CLL, lymphoma, nanoparticles, chlorambucil, hydroxychloroquine, rituximab.
Abstract: The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.
Export Options
About this article
Cite this article as:
H. Marin Gustavo, Mansilla Eduardo, Mezzaroba Nelly, Zorzet Sonia, Nunez Luis, Larsen Gustavo, M. Tau Jose, Maceira Alberto, Spretz Ruben, Mertz Carol, Ingrao Sabrina, Tripodo Claudio, Tedesco Francesco and Macor Paolo, Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma, Current Clinical Pharmacology 2010; 5 (4) . https://dx.doi.org/10.2174/157488410793352058
DOI https://dx.doi.org/10.2174/157488410793352058 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development
Current Medicinal Chemistry Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry Melatonin Attenuates Methamphetamine-Induced Neurotoxicity
Current Pharmaceutical Design Editorial (Thematic Issue: Clonal Heterogeneity and Diversification in B-cell Disorders)
Current Cancer Therapy Reviews Growth Factors as Therapeutics for Diabetic Neuropathy
Current Drug Targets P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets Interventional Radiology in Paediatrics
Current Pediatric Reviews Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Histopathology of Connective Tissue Disease-Associated Pleuropulmonary Disease
Current Respiratory Medicine Reviews The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry